KR20090097194A - 바이사이클 피리미디논 및 그 용도 - Google Patents
바이사이클 피리미디논 및 그 용도 Download PDFInfo
- Publication number
- KR20090097194A KR20090097194A KR1020097014886A KR20097014886A KR20090097194A KR 20090097194 A KR20090097194 A KR 20090097194A KR 1020097014886 A KR1020097014886 A KR 1020097014886A KR 20097014886 A KR20097014886 A KR 20097014886A KR 20090097194 A KR20090097194 A KR 20090097194A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- hydroxy
- pyrimidine
- oxo
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *Cc(cc1Cl)ccc1Cl Chemical compound *Cc(cc1Cl)ccc1Cl 0.000 description 3
- LJWGSBLBOFUSDK-UHFFFAOYSA-N CC(C)C(SC1=NC(C(OC)=O)=C2O)=CN1C2=O Chemical compound CC(C)C(SC1=NC(C(OC)=O)=C2O)=CN1C2=O LJWGSBLBOFUSDK-UHFFFAOYSA-N 0.000 description 1
- ZIKJYUFMWJZUDI-UHFFFAOYSA-N CC(C)c1ncc(-c(cc2)ccc2F)[o]1 Chemical compound CC(C)c1ncc(-c(cc2)ccc2F)[o]1 ZIKJYUFMWJZUDI-UHFFFAOYSA-N 0.000 description 1
- HLRDZNFRPOQRLL-UHFFFAOYSA-N CC(C=CC1=NC(C(NCC(c2ccccc2)=O)=O)=C2OCc3ccccc3)=CN1C2=O Chemical compound CC(C=CC1=NC(C(NCC(c2ccccc2)=O)=O)=C2OCc3ccccc3)=CN1C2=O HLRDZNFRPOQRLL-UHFFFAOYSA-N 0.000 description 1
- BCLDYFAYRMPLFE-UHFFFAOYSA-N CC(C=CC1=NC(c2n[o]c(Cc(cc3)ccc3F)n2)=C2O)=CN1C2=O Chemical compound CC(C=CC1=NC(c2n[o]c(Cc(cc3)ccc3F)n2)=C2O)=CN1C2=O BCLDYFAYRMPLFE-UHFFFAOYSA-N 0.000 description 1
- OMHNZQHMIZHOQF-UHFFFAOYSA-N CC(C=CC1=NC(c2ncc(-c(cc3)ccc3F)[o]2)=C2O)=CN1C2=O Chemical compound CC(C=CC1=NC(c2ncc(-c(cc3)ccc3F)[o]2)=C2O)=CN1C2=O OMHNZQHMIZHOQF-UHFFFAOYSA-N 0.000 description 1
- VUDWKWROVMHUAY-UHFFFAOYSA-N CC(C=CC1=NC(c2ncc(-c3ccccc3)[o]2)=C2O)=CN1C2=O Chemical compound CC(C=CC1=NC(c2ncc(-c3ccccc3)[o]2)=C2O)=CN1C2=O VUDWKWROVMHUAY-UHFFFAOYSA-N 0.000 description 1
- QSHUCICZRVXTIZ-UHFFFAOYSA-N CC(C=CC1=NC(c2ncc(-c3ccccc3)[o]2)=C2OCc3ccccc3)=CN1C2=O Chemical compound CC(C=CC1=NC(c2ncc(-c3ccccc3)[o]2)=C2OCc3ccccc3)=CN1C2=O QSHUCICZRVXTIZ-UHFFFAOYSA-N 0.000 description 1
- NHOVDTSXHGUSTK-UHFFFAOYSA-N CC(C=CC1=NC(c2ncc(-c3ccccc3)[s]2)=C2O)=CN1C2=O Chemical compound CC(C=CC1=NC(c2ncc(-c3ccccc3)[s]2)=C2O)=CN1C2=O NHOVDTSXHGUSTK-UHFFFAOYSA-N 0.000 description 1
- SQYXCPCNPAUUNE-UHFFFAOYSA-N CC(C=CC1=NC(c2ncc(-c3ccccc3)[s]2)=C2OCc3ccccc3)=CN1C2=O Chemical compound CC(C=CC1=NC(c2ncc(-c3ccccc3)[s]2)=C2OCc3ccccc3)=CN1C2=O SQYXCPCNPAUUNE-UHFFFAOYSA-N 0.000 description 1
- LZXUZOBDEKSZPR-UHFFFAOYSA-N CC(C=CC1=NC(c2nnc(Cc(cc3Cl)ccc3Cl)[s]2)=C2O)=CN1C2=O Chemical compound CC(C=CC1=NC(c2nnc(Cc(cc3Cl)ccc3Cl)[s]2)=C2O)=CN1C2=O LZXUZOBDEKSZPR-UHFFFAOYSA-N 0.000 description 1
- NUNJVNQFSSLROH-UHFFFAOYSA-N CN(c(cccc1)c1C1=NC(C(NCc(cc2)ccc2F)=O)=C2O)N1C2=O Chemical compound CN(c(cccc1)c1C1=NC(C(NCc(cc2)ccc2F)=O)=C2O)N1C2=O NUNJVNQFSSLROH-UHFFFAOYSA-N 0.000 description 1
- VOEZTSHWBOMTSU-UHFFFAOYSA-N CNCC(SC1=NC(C(NCc(cc2Cl)ccc2Cl)=O)=C2O)=CN1C2=O Chemical compound CNCC(SC1=NC(C(NCc(cc2Cl)ccc2Cl)=O)=C2O)=CN1C2=O VOEZTSHWBOMTSU-UHFFFAOYSA-N 0.000 description 1
- CMPZQBFZPXHDCN-UHFFFAOYSA-N COC(C(N=C(C=CC(Br)=C1)N1C1=O)=C1O)=O Chemical compound COC(C(N=C(C=CC(Br)=C1)N1C1=O)=C1O)=O CMPZQBFZPXHDCN-UHFFFAOYSA-N 0.000 description 1
- CYXRJUQXIDDPGS-UHFFFAOYSA-N COC(C(N=C(C=CC(Cl)=C1)N1C1=O)=C1O)=O Chemical compound COC(C(N=C(C=CC(Cl)=C1)N1C1=O)=C1O)=O CYXRJUQXIDDPGS-UHFFFAOYSA-N 0.000 description 1
- QZUIWCRNRQXGNQ-UHFFFAOYSA-N COC(C(N=C(C=CC(N1CCOCC1)=C1)N1C1=O)=C1O)=O Chemical compound COC(C(N=C(C=CC(N1CCOCC1)=C1)N1C1=O)=C1O)=O QZUIWCRNRQXGNQ-UHFFFAOYSA-N 0.000 description 1
- GXKXHKZYLLLQPM-UHFFFAOYSA-N COC(C(N=C1N(C2=O)NC=C1)=C2O)=O Chemical compound COC(C(N=C1N(C2=O)NC=C1)=C2O)=O GXKXHKZYLLLQPM-UHFFFAOYSA-N 0.000 description 1
- AWGXGKSNAUAFHT-UHFFFAOYSA-N COCN1CCN(CCN(c(cccc2)c2N2C3=O)C2=NC(C(NCc(cc2)cc(Cl)c2Cl)=O)=C3O)CC1 Chemical compound COCN1CCN(CCN(c(cccc2)c2N2C3=O)C2=NC(C(NCc(cc2)cc(Cl)c2Cl)=O)=C3O)CC1 AWGXGKSNAUAFHT-UHFFFAOYSA-N 0.000 description 1
- UHXINIQONIMXFE-UHFFFAOYSA-N Cc(c(C)c1)cc(NC2=NC(C(NCc(cc3Cl)ccc3Cl)=O)=C3O)c1N2C3=O Chemical compound Cc(c(C)c1)cc(NC2=NC(C(NCc(cc3Cl)ccc3Cl)=O)=C3O)c1N2C3=O UHXINIQONIMXFE-UHFFFAOYSA-N 0.000 description 1
- IWKAINRWDUQWDM-UHFFFAOYSA-M N#CC(C1=NC(C(NCc(cc2Cl)ccc2Cl)=O)=C2[O-])=CNN1C2=O Chemical compound N#CC(C1=NC(C(NCc(cc2Cl)ccc2Cl)=O)=C2[O-])=CNN1C2=O IWKAINRWDUQWDM-UHFFFAOYSA-M 0.000 description 1
- ACYSKLGOADDKAI-UHFFFAOYSA-N Nc(cc1)ncc1N1CCOCC1 Chemical compound Nc(cc1)ncc1N1CCOCC1 ACYSKLGOADDKAI-UHFFFAOYSA-N 0.000 description 1
- JVVRJMXHNUAPHW-UHFFFAOYSA-N Nc1n[nH]cc1 Chemical compound Nc1n[nH]cc1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 1
- IDVSKPCYJJKGJR-UHFFFAOYSA-N OC(C1=O)=C(C(NCc(cc2Cl)ccc2Cl)=O)N=C2N1NC=C2Br Chemical compound OC(C1=O)=C(C(NCc(cc2Cl)ccc2Cl)=O)N=C2N1NC=C2Br IDVSKPCYJJKGJR-UHFFFAOYSA-N 0.000 description 1
- TUPYKYMFOUOSFI-UHFFFAOYSA-N OC1=C(C(NCc(cc2)cc(Cl)c2Cl)=O)N=C(C=CC(Cl)=C2)N2C1=O Chemical compound OC1=C(C(NCc(cc2)cc(Cl)c2Cl)=O)N=C(C=CC(Cl)=C2)N2C1=O TUPYKYMFOUOSFI-UHFFFAOYSA-N 0.000 description 1
- XLLWYTPXRFLMIZ-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C=C(C=C2)N3CCOCC3)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C=C(C=C2)N3CCOCC3)N2C1=O XLLWYTPXRFLMIZ-UHFFFAOYSA-N 0.000 description 1
- HULSTKMEQFJGQI-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C=CC(N(CCCC2)S2(=O)=O)=C2)N2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C(C=CC(N(CCCC2)S2(=O)=O)=C2)N2C1=O HULSTKMEQFJGQI-UHFFFAOYSA-N 0.000 description 1
- VFACFATYTSAQFC-UHFFFAOYSA-N OC1=C(C(NCc(cc2)ccc2F)=O)N=C2SC(CN3CCOCC3)=CN2C1=O Chemical compound OC1=C(C(NCc(cc2)ccc2F)=O)N=C2SC(CN3CCOCC3)=CN2C1=O VFACFATYTSAQFC-UHFFFAOYSA-N 0.000 description 1
- HWHKZEVMJYAHRP-UHFFFAOYSA-N OC1=C(C(NCc(cc2Cl)ccc2Cl)=O)N=C(Nc2c3cccc2)N3C1=O Chemical compound OC1=C(C(NCc(cc2Cl)ccc2Cl)=O)N=C(Nc2c3cccc2)N3C1=O HWHKZEVMJYAHRP-UHFFFAOYSA-N 0.000 description 1
- RQLSGLDJGCBAAS-UHFFFAOYSA-N [O-]Nc(cc1)ncc1Br Chemical compound [O-]Nc(cc1)ncc1Br RQLSGLDJGCBAAS-UHFFFAOYSA-N 0.000 description 1
- FXPDMLHZJNVFCN-UHFFFAOYSA-N [O-]Nc(nc1)ccc1N1CCOCC1 Chemical compound [O-]Nc(nc1)ccc1N1CCOCC1 FXPDMLHZJNVFCN-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006907283 | 2006-12-22 | ||
| AU2006907283A AU2006907283A0 (en) | 2006-12-22 | Bicyclic pyrimidinones and uses thereof | |
| AU2007902479 | 2007-05-09 | ||
| AU2007902479A AU2007902479A0 (en) | 2007-05-09 | Bicyclic pyrimidinones and uses thereof (2) | |
| AU2007903401 | 2007-06-25 | ||
| AU2007903401A AU2007903401A0 (en) | 2007-06-25 | Bicyclic pyrimidinodes and uses thereof (3) | |
| AU2007904114 | 2007-07-31 | ||
| AU2007904114A AU2007904114A0 (en) | 2007-07-31 | Bicyclic pyrimidinones and uses thereof (4) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107008711A Division KR20100049698A (ko) | 2006-12-22 | 2007-12-21 | 바이사이클 피리미디논 및 그 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090097194A true KR20090097194A (ko) | 2009-09-15 |
Family
ID=39562030
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097014886A Ceased KR20090097194A (ko) | 2006-12-22 | 2007-12-21 | 바이사이클 피리미디논 및 그 용도 |
| KR1020107008711A Ceased KR20100049698A (ko) | 2006-12-22 | 2007-12-21 | 바이사이클 피리미디논 및 그 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107008711A Ceased KR20100049698A (ko) | 2006-12-22 | 2007-12-21 | 바이사이클 피리미디논 및 그 용도 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8143268B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2114903B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5208962B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20090097194A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101880280B (cg-RX-API-DMAC7.html) |
| AR (2) | AR064517A1 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE496898T1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2007336703B9 (cg-RX-API-DMAC7.html) |
| BR (2) | BRPI0720564A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2673183C (cg-RX-API-DMAC7.html) |
| DE (1) | DE602007012308D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2114903T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009006764A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ577491A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008077188A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318732B2 (en) * | 2008-07-02 | 2012-11-27 | Avexa Limited | Compounds having antiviral properties |
| WO2010000031A1 (en) * | 2008-07-02 | 2010-01-07 | Avexa Limited | Imidazopyrimidinones and uses thereof |
| EP2247601B1 (en) * | 2008-07-02 | 2013-04-10 | Avexa Limited | Thiazopyrimidinones and uses thereof |
| CN102336751A (zh) * | 2010-07-16 | 2012-02-01 | 爱维艾珂瑟有限公司 | 新型抗病毒剂 |
| CN105764904B (zh) | 2013-09-12 | 2020-02-11 | 詹森生物制药有限公司 | 氮杂-吡啶酮化合物及其用途 |
| WO2015105657A1 (en) * | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2016145103A1 (en) | 2015-03-11 | 2016-09-15 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| JP2019535789A (ja) | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| US12195458B2 (en) | 2019-12-02 | 2025-01-14 | Storm Therapeutics Limited | Polyheterocyclic compounds as METTL3 inhibitors |
| US12070445B2 (en) * | 2021-08-27 | 2024-08-27 | Wisconsin Alumni Research Foundation | System and assay for monitoring production/release of membrane-lytic toxins in bacteria and compounds for modulating same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002044141A2 (en) | 2000-09-20 | 2002-06-06 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists |
| US7176220B2 (en) | 2002-11-20 | 2007-02-13 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
| ATE435222T1 (de) | 2003-12-18 | 2009-07-15 | Tibotec Pharm Ltd | Aminobenzimidazole und benzimidazole als inhibitoren der replikation von respiratory syncytial virus |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| MX2007004403A (es) | 2004-10-12 | 2007-04-27 | Astrazeneca Ab | Derivados de quinazolina. |
| WO2006103399A1 (en) | 2005-03-31 | 2006-10-05 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| JP5094725B2 (ja) | 2005-10-04 | 2012-12-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Ｈｉｖインテグラーゼ阻害剤 |
-
2007
- 2007-12-21 AR ARP070105884A patent/AR064517A1/es not_active Application Discontinuation
- 2007-12-21 DE DE602007012308T patent/DE602007012308D1/de active Active
- 2007-12-21 EP EP07855368A patent/EP2114903B1/en active Active
- 2007-12-21 BR BRPI0720564-3A patent/BRPI0720564A2/pt not_active IP Right Cessation
- 2007-12-21 WO PCT/AU2007/001980 patent/WO2008077188A1/en not_active Ceased
- 2007-12-21 JP JP2009541695A patent/JP5208962B2/ja not_active Expired - Fee Related
- 2007-12-21 EP EP10164218A patent/EP2269992A1/en not_active Withdrawn
- 2007-12-21 AU AU2007336703A patent/AU2007336703B9/en not_active Ceased
- 2007-12-21 AT AT07855368T patent/ATE496898T1/de not_active IP Right Cessation
- 2007-12-21 BR BRPI0722411-7A patent/BRPI0722411A2/pt active Search and Examination
- 2007-12-21 CN CN201010148170.6A patent/CN101880280B/zh not_active Expired - Fee Related
- 2007-12-21 DK DK07855368.2T patent/DK2114903T3/da active
- 2007-12-21 NZ NZ577491A patent/NZ577491A/en not_active IP Right Cessation
- 2007-12-21 KR KR1020097014886A patent/KR20090097194A/ko not_active Ceased
- 2007-12-21 KR KR1020107008711A patent/KR20100049698A/ko not_active Ceased
- 2007-12-21 US US12/519,273 patent/US8143268B2/en not_active Expired - Fee Related
- 2007-12-21 MX MX2009006764A patent/MX2009006764A/es active IP Right Grant
- 2007-12-21 CA CA2673183A patent/CA2673183C/en not_active Expired - Fee Related
-
2010
- 2010-03-24 AU AU2010201160A patent/AU2010201160A1/en not_active Abandoned
- 2010-04-23 US US12/766,510 patent/US8207334B2/en not_active Expired - Fee Related
- 2010-06-07 JP JP2010129801A patent/JP2010222370A/ja not_active Withdrawn
- 2010-06-09 AR ARP100102037A patent/AR077043A2/es unknown
-
2012
- 2012-02-27 US US13/405,511 patent/US8859563B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5208962B2 (ja) | 二環式ピリミジノンおよびその使用 | |
| JP5535204B2 (ja) | 抗ウイルス特性を有する化合物 | |
| CA2409743C (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
| JP2012514044A (ja) | Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物 | |
| CN105164135A (zh) | 4-取代的吡咯并二氮杂卓和吡唑并二氮杂卓 | |
| JP2003321472A (ja) | Ｇｒｋ阻害剤 | |
| CA2729656A1 (en) | Imidazopyrimidinones and uses thereof | |
| JP2022517085A (ja) | ハロゲン化アリルアミン系化合物及びその適用 | |
| CN101627019B (zh) | 双环嘧啶酮以及其应用 | |
| ES2358550T3 (es) | Pirimidinonas bicíclicas y sus usos. | |
| JP2022534495A (ja) | 融合複素環式誘導体 | |
| HK1131615B (en) | Bicyclic pyrimidinones and uses thereof | |
| BR112020005934A2 (pt) | inibidor de pde9 e uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20090716 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20100421 |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20100421 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20111216 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20120717 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20111216 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |